Search NLS News

Ultimovacs has announced that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer. DOVACC  is organized with two influential European networks of gynaecological oncologists; the Nordic Society […]

Cyxone has announced results from a phase 2 study of Rabeximod in Covid-19 patients with moderate disease. The primary endpoint, ultimately proposed by the FDA, was to document the difference of the proportion of subjects alive and free of respiratory failure at day 28 between placebo (standard of care treatment) and Rabeximod plus standard of […]

Finding and securing talent is critical for the growth of the life sciences sector, this is widely accepted. The ever-present questions are how to keep up with the demand and with whom the responsibility rests to solve the skills supply challenge. The pressure is real for every segment of the life science ecosystem here in […]

Evusheld (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. The Food and Drug Administration (FDA) granted the EUA for Evusheld for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due […]

Elypta announces the enrollment of the first patient in the newly initiated AURORAX-0093A (AUR93A) study. AUR93A is intended to explore Elypta’s metabolism-based liquid biopsy platform for the prognosis of muscle-invasive bladder cancer (MIBC) before neo-adjuvant chemotherapy. The first patient was enrolled at San Raffaele Hospital, Milan, Italy. AUR93A In AUR93A, Elypta is exploring the prognostic […]

Xbrane Biopharma has announced the initiation of developing two new biosimilar candidates referencing Keytruda and Darzalex respectively. Together with the continued development of Xdivane, a biosimilar candidate referencing Opdivo, this forms an oncology biosimilar portfolio addressing 23 billion EUR of combined annual reference product sales, states the company. Keytruda and Darzalex biosimilars Keytruda is a […]

The last manufacturing steps of the company’s Evusheld (previously AZD7442) will take place in Södertälje, Sweden. Packaging and release of the potential new drug, a combination of long-acting antibodies that both prevent and treat COVID-19, has already begun in Södertälje – AstraZeneca’s largest facility within its global production network. The plan is to increase production […]

Novo Nordisk has announced plans to invest more than 17 billion Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.​ The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to […]

New results from the DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a higher progression-free survival (PFS) and objective response rate (ORR) in pre-specified patient subgroups compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Enhertu is a HER2-directed antibody drug conjugate […]

Together with CymaBay Therapeutics Inficure Bio have co-presented positive data at the American Association for the study of Liver Diseases (AASLD). Inficure and CymaBay performed a functional study in the NIF mouse model using seladelpar, a selective peroxisome proliferator (PPAR) delta agonist currently in a Phase 3 study for Primary Biliary Cholangitis (PBC). The goal […]